Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 6/20 | 0.37 |
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | SLC15A2 | Q16348 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6543286 | 1.00 | ALDH1A1 (0.37) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6543035 | 0.92 | NR1I2 (0.41) | HSD17B10MAPTTDP1KMT2ANR1I2 | |
| SCHEMBL6543086 | 0.89 | KCNH2 (0.39) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6543084 | 0.89 | KCNH2 (0.39) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6541755 | 0.89 | KCNH2 (0.38) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6541751 | 0.89 | KCNH2 (0.38) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6542128 | 0.88 | KCNH2 (0.39) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6542123 | 0.88 | KCNH2 (0.39) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6541950 | 0.86 | ALDH1A1 (0.48) | ALDH1A1HSD17B10MAPTKDM4ETDP1 | |
| SCHEMBL6542342 | 0.85 | ALDH1A1 (0.41) | ALDH1A1HSD17B10MAPTKDM4ETDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1333836-A4 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS INC (US) | 2004-07-07 | — | — | EP | disclosed |
| EP-1333836-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | Essential Therapeutics, Inc. (US) | 2003-08-13 | — | — | EP | disclosed |
| US-6599893-B2 | Such as (7R)-7-(2-(2-amino-5-chlorothiazol-4-yl)-2-trityl-oxyiminoacetylamino)-3-(4 -methyl-(1,2, 3)thiadiazol-5-ylsulfanyl)-8-oxo-5-thia-1-aza-bicyclo(4.2.0)oct-2-ene-2 -carboxylic acid benzhydryl ester; methicillin-resistance | ESSENTIAL THERAPEUTICS, INC. | 2003-07-29 | — | — | US | disclosed |
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | MICROCIDE PHARMACEUTICALS. | 2002-08-22 | — | — | US | disclosed |
| WO-2002017854-A2 | CEPHALOSPORIN ANTIBIOTICS AND PRODRUGS THEREOF | ESSENTIAL THERAPEUTICS, INC. (US) | 2002-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020115650-A1 | Cephalosporin antibiotics and prodrugs thereof | PEPD, ABCG2, ABCC1 | ALDH1A1 1134/4885HSD17B10 701/4885MAPT 3278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.